ATE474560T1 - Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit - Google Patents
Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheitInfo
- Publication number
- ATE474560T1 ATE474560T1 AT06820527T AT06820527T ATE474560T1 AT E474560 T1 ATE474560 T1 AT E474560T1 AT 06820527 T AT06820527 T AT 06820527T AT 06820527 T AT06820527 T AT 06820527T AT E474560 T1 ATE474560 T1 AT E474560T1
- Authority
- AT
- Austria
- Prior art keywords
- tenofovir
- lamivudine
- nucleotide
- reverse transcriptase
- different parts
- Prior art date
Links
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 title 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 title 1
- 229960001627 lamivudine Drugs 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title 1
- 229960004556 tenofovir Drugs 0.000 title 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1566MU2005 | 2005-12-14 | ||
| IN1878MU2006 | 2006-11-13 | ||
| PCT/GB2006/004687 WO2007068934A2 (en) | 2005-12-14 | 2006-12-14 | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE474560T1 true ATE474560T1 (de) | 2010-08-15 |
Family
ID=38163276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06820527T ATE474560T1 (de) | 2005-12-14 | 2006-12-14 | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080317852A1 (https=) |
| EP (1) | EP2051703B1 (https=) |
| JP (1) | JP5231242B2 (https=) |
| KR (1) | KR20080091767A (https=) |
| AP (1) | AP2008004533A0 (https=) |
| AT (1) | ATE474560T1 (https=) |
| AU (1) | AU2006325404B2 (https=) |
| BR (1) | BRPI0620705A2 (https=) |
| CA (1) | CA2633603C (https=) |
| DE (1) | DE602006015721D1 (https=) |
| MA (1) | MA30161B1 (https=) |
| NZ (1) | NZ569349A (https=) |
| RU (1) | RU2008128424A (https=) |
| SI (1) | SI2051703T1 (https=) |
| WO (1) | WO2007068934A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007016A (es) | 2003-01-14 | 2005-09-12 | Gilead Sciences Inc | Composiciones y metodos para terapia antiviral de combinacion. |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| WO2009037449A1 (en) * | 2007-09-18 | 2009-03-26 | Cipla Limited | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| GT200800303A (es) * | 2007-12-24 | 2009-09-18 | Combinacion anti-retroviral | |
| WO2009106954A1 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable dosage forms of lamivudine and tenofovir |
| WO2009106960A2 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| DK2393485T3 (en) * | 2009-02-06 | 2015-10-26 | Gilead Sciences Inc | Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir |
| WO2010125572A1 (en) * | 2009-04-29 | 2010-11-04 | Hetero Research Foundation | Compressed tablets and capsules containing efavirenz |
| US8481554B2 (en) | 2009-05-27 | 2013-07-09 | Hetero Research Foundation | Solid oral dosage forms of lamivudine |
| EP2389929A1 (en) * | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of tenofovir |
| CN114010776A (zh) | 2010-06-09 | 2022-02-08 | 疫苗技术股份有限公司 | 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫 |
| SG10201509521WA (en) | 2010-11-19 | 2015-12-30 | Gilead Sciences Inc | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
| CA2835272A1 (en) * | 2011-05-30 | 2012-12-06 | Cipla Limited | Pharmaceutical antiretroviral composition |
| CN103211826A (zh) * | 2013-05-14 | 2013-07-24 | 福建广生堂药业股份有限公司 | 一种抗病毒药物组合物及其制备方法和用途 |
| EP2832351A1 (en) * | 2013-07-29 | 2015-02-04 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multilayer Tablet Formulations Comprising Tenofovir and Entecavir |
| AU2015290400B2 (en) * | 2014-07-18 | 2017-12-07 | Jw Pharmaceutical Corporation | Novel salt of tenofovir disoproxil |
| CN104473896B (zh) * | 2014-12-01 | 2017-04-19 | 东莞市金美济药业有限公司 | 一种快速崩解的拉米夫定片及其制备工艺 |
| WO2017095761A1 (en) | 2015-12-02 | 2017-06-08 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
| TR201617448A2 (tr) | 2016-11-29 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler |
| CN106822155B (zh) * | 2016-12-29 | 2019-10-11 | 东北制药集团股份有限公司 | 依非韦伦、拉米夫定及富马酸替诺福韦酯三联复方片中片及其制备方法 |
| RU2644156C1 (ru) | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
| RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE556141A (https=) * | 1956-03-27 | |||
| CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5366972A (en) * | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
| US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| US5665720A (en) * | 1992-08-07 | 1997-09-09 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5733788A (en) * | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| GB9820420D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| ZA200110501B (en) * | 2001-05-11 | 2002-04-03 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
| ZA200110499B (en) * | 2001-05-11 | 2002-04-03 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| AU2002311622A1 (en) * | 2002-04-23 | 2003-11-10 | Lupin Limited | Long acting compositions comprising zidovudine and lamivudine |
| AU2003231765B9 (en) * | 2002-04-26 | 2010-01-28 | Gilead Sciences, Inc. | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such |
| US20050287177A1 (en) * | 2002-11-08 | 2005-12-29 | Glaxo Group Unlimited And Smithkline Beecham Corp. | Pharmaceutical compositions |
| MXPA05007016A (es) * | 2003-01-14 | 2005-09-12 | Gilead Sciences Inc | Composiciones y metodos para terapia antiviral de combinacion. |
| US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
-
2006
- 2006-12-14 AT AT06820527T patent/ATE474560T1/de not_active IP Right Cessation
- 2006-12-14 JP JP2008545090A patent/JP5231242B2/ja active Active
- 2006-12-14 EP EP06820527A patent/EP2051703B1/en not_active Not-in-force
- 2006-12-14 RU RU2008128424/15A patent/RU2008128424A/ru not_active Application Discontinuation
- 2006-12-14 AP AP2008004533A patent/AP2008004533A0/xx unknown
- 2006-12-14 KR KR1020087016727A patent/KR20080091767A/ko not_active Ceased
- 2006-12-14 CA CA2633603A patent/CA2633603C/en not_active Expired - Fee Related
- 2006-12-14 US US12/097,387 patent/US20080317852A1/en not_active Abandoned
- 2006-12-14 DE DE602006015721T patent/DE602006015721D1/de active Active
- 2006-12-14 AU AU2006325404A patent/AU2006325404B2/en not_active Ceased
- 2006-12-14 BR BRPI0620705-7A patent/BRPI0620705A2/pt not_active IP Right Cessation
- 2006-12-14 SI SI200630809T patent/SI2051703T1/sl unknown
- 2006-12-14 NZ NZ569349A patent/NZ569349A/en unknown
- 2006-12-14 WO PCT/GB2006/004687 patent/WO2007068934A2/en not_active Ceased
-
2008
- 2008-07-11 MA MA31114A patent/MA30161B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006015721D1 (de) | 2010-09-02 |
| JP2009519311A (ja) | 2009-05-14 |
| EP2051703B1 (en) | 2010-07-21 |
| SI2051703T1 (sl) | 2011-01-31 |
| CA2633603C (en) | 2016-09-13 |
| CA2633603A1 (en) | 2007-06-21 |
| JP5231242B2 (ja) | 2013-07-10 |
| WO2007068934A3 (en) | 2008-02-21 |
| WO2007068934A2 (en) | 2007-06-21 |
| AU2006325404A1 (en) | 2007-06-21 |
| KR20080091767A (ko) | 2008-10-14 |
| BRPI0620705A2 (pt) | 2011-11-22 |
| NZ569349A (en) | 2012-01-12 |
| RU2008128424A (ru) | 2010-01-20 |
| EP2051703A2 (en) | 2009-04-29 |
| AP2008004533A0 (en) | 2008-08-31 |
| AU2006325404B2 (en) | 2012-03-01 |
| US20080317852A1 (en) | 2008-12-25 |
| MA30161B1 (fr) | 2009-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE474560T1 (de) | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit | |
| CY2017029I1 (el) | ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ | |
| ATE542815T1 (de) | Kokristalle und pharmazeutische zusammensetzungen damit | |
| CL2007002649A1 (es) | Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes. | |
| DK3072504T3 (da) | Orale transmukosale doseringsformer i små volumener | |
| EP1992348A4 (en) | PHARMACEUTICAL COMBINATION | |
| IL184758A0 (en) | New pharmaceutical compositions useful in the transmucosal administration of drugs | |
| IL188732A (en) | Use of ibuprofen and famotidine in the preparation of medicaments | |
| HUE043492T2 (hu) | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására | |
| IL199151A (en) | Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits | |
| IL191140A0 (en) | Aminopyrimidine derivatives and pharmaceutical compositions containing the same | |
| ATE419839T1 (de) | Trockengranulierungzusammensetzung enthaltend emtricitabine und tenofovir df | |
| IL188744A0 (en) | High drug load formulations and dosage forms | |
| DK2234968T3 (da) | (aza)indolderivat substitueret i position 5, farmaceutisk sammensætning omfattende det, mellemliggende forbindelser og fremstillingsproces dertil | |
| ATE530546T1 (de) | Kokristalle und pharmazeutische zusammensetzungen damit | |
| IL186102A0 (en) | Alpha ketoamide derivatives and pharmaceutical compositions containing the same | |
| PL2839836T3 (pl) | Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego | |
| IL179253A (en) | The history of pyrimidine and its pharmaceutical preparations | |
| DK1808446T3 (da) | IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten | |
| DE602005004039D1 (de) | Nicht-peptidische bradykinin-antagonisten und pharmazeutische zusammensetzungen daraus | |
| EP1900813A4 (en) | NESFATIN, A NEW PHYSIOLOGICAL SUBSTANCE, SUBSTANCE IN CONNECTION WITH THIS AND THE USE OF THE SUBSTANCES | |
| EP1756091A4 (en) | NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | |
| EP2156832A4 (en) | PHARMACEUTICAL COMPOSITION | |
| DE602005012287D1 (de) | Biotinylierte hexadecasaccharide, pharmazeutische zusammensetzungen daraus und deren verwendung | |
| PT1865966E (pt) | Uso de fármacos anti-inflamatórios não esteróides por inalação no tratamento de bronquite aguda e crónica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |